Luye Pharma Initiates Phase II Trial of LY03017 for Alzheimer’s-Associated Psychosis in China Following US Clinical Clearance
Luye Pharma Group Limited (HKG: 2186) has announced the initiation of a Phase II clinical...
Drug
Zai Lab and Boehringer Ingelheim Partner on DLL3 Combination Therapy for Neuroendocrine Cancers
Zai Lab (NASDAQ: ZLAB, HKG: 9688) and Boehringer Ingelheim (BI) have announced a strategic clinical...
Johnson & Johnson Partners with Shanghai Pharmaceuticals for Exclusive Promotion of Paliperidone Palmitate Long-Acting Injection in China
Johnson & Johnson (J&J, NYSE: JNJ) has entered into an exclusive marketing promotion agreement with...
Fosun Pharma Advances Dual-Target CAR-T Therapy FKC289 into Clinical Trials for Rare Kidney and Blood Disorders
Shanghai Fosun Pharmaceutical Group Co., Ltd. (SHA: 600196, HKG: 2196) announced it has received regulatory...
Gan & Lee Pharmaceuticals Doses First Patient in Phase III Trial for Novel Long-Acting Insulin GZR33 in Type 2 Diabetes
Gan & Lee Pharmaceuticals (SHA: 603087) announced the first subject dosing in a Phase III...
Huadong Medicine’s Semaglutide Biosimilar HDM1702 Enters NMPA Review for Weight Management Indication
Huadong Medicine Co., Ltd. (SHE: 000963) announced that the National Medical Products Administration (NMPA) has...
Laekna Therapeutics Reports Breakthrough Phase III Results for LAE002 AKT Inhibitor in HR+/HER2- Breast Cancer
Laekna Therapeutics Shanghai Co., Ltd. (HKG: 2105) announced positive top-line results from a Phase III...
Xuanzhu Biopharma Receives NMPA Approval for Phase III Trial of Anaprazole-Based Quadruple Therapy Against H. pylori
Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced it has received regulatory clearance from the National...
Shanghai Henlius Biotech Launches Phase I Trial for HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer
Shanghai Henlius Biotech, Inc. (HKG: 2696), a leading Chinese biopharmaceutical company, announced it has received...
Ribo Life Science Advances World’s Leading FXI-Targeting siRNA Vortosiran into Phase IIb for AF Stroke Prevention
Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) announced it has submitted an approval filing...
Daiichi Sankyo-Merck Ifinatamab Deruxtecan Granted FDA Priority Review for Extensive-Stage SCLC
Daiichi Sankyo (TYO: 4568) and Merck & Co., Inc. (MSD; NYSE: MRK) announced that the...
CureGene’s CG-0255 Receives NMPA Approval for Ischemic Stroke Trial – First Thiol-Based P2Y12 Inhibitor
Shanghai CureGene Pharmaceutical Co., Ltd announced it has received clinical trial approval from China’s National...
Grand Pharmaceutical’s SIR-Spheres Achieves Phase III Success in Unresectable HCC, Supporting China Expansion
Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced that the Phase III clinical trial for...
Zelgen’s Jaktinib Hits Primary Endpoint in Phase III Atopic Dermatitis Trial – Dual JAK/ACVR1 Inhibitor Expands Beyond Myelofusion
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that its Phase III clinical trial evaluating...
Youcare Pharmaceutical Advances Dual mRNA Vaccine Pipeline with NMPA Approvals for RSV and Herpes Zoster Candidates
Youcare Pharmaceutical Group (SHA: 688658) announced separate clinical trial approvals from China’s National Medical Products...
Eli Lilly’s Jaypirca Combination Therapy Demonstrates Significant PFS Benefit in Phase III CLL/SLL Trial – Non-Covalent BTK Inhibitor Shows Promise Regardless of Prior Treatment History
Eli Lilly and Company (NYSE: LLY) announced positive topline results from the Phase III BRUIN...
Sanofi Secures EC Approval for Dupixent in Pediatric Chronic Spontaneous Urticaria – First Biologic Therapy for Children 2–11 Years
Sanofi SA (NASDAQ: SNY) announced that the European Commission (EC) has granted marketing authorization for...
AstraZeneca’s Imjudo Gains NMPA Approval for First-Line NSCLC in China, Backed by POSEIDON Data
AstraZeneca plc (NYSE: AZN) has secured marketing approval from China’s National Medical Products Administration (NMPA)...
RemeGen’s Disitamab Vedotin Wins World’s First HER2-ADC Approval for First-Line Advanced Urothelial Carcinoma
RemeGen Ltd. (HKG: 9995) has announced that China’s National Medical Products Administration (NMPA) has approved...
Henlius Biotech Doses First Patient in Phase I Trial for HLX319, a Biosimilar to Roche’s Phesgo
Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the dosing of the first subject in...